Plomer Manuel, de Zeeuw Justus
Medical Affairs CHC Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, D-65926, Frankfurt am Main, Deutschland.
, Köln, Deutschland.
MMW Fortschr Med. 2017 Jun;159(Suppl 5):22-33. doi: 10.1007/s15006-017-9805-0. Epub 2017 Jun 22.
Ambroxol has been established for decades in the treatment of acute and chronic respiratory diseases. In 2015, the European Medicines Agency reassessed the clinical benefit-risk ratio of the drug.
What new scientific data on ambroxol, which are relevant to the treatment of bronchopulmonary diseases, are available?
The review is based on a systematic literature research in medline with the search term "ambroxol" during the publication period 2006-2015. Non-relevant publications were excluded manually.
Ambroxol is still intensively researched. The traditional indication as an expectorant is confirmed. But there is also an ever better understanding of the various mechanisms of action as well as the ever more exact modeling of the structures under investigation. New fields of application are conceivable, e. g. in patients with severe pulmonary disease who undergo surgery or who are in intensive care, as an adjuvant in anti-infective therapies, especially in infections with biofilm-producing pathogens, or in rare diseases such as lysosomal storage diseases. However, final evidence of the clinical relevance in these fields of application is still missing.
氨溴索已用于治疗急慢性呼吸道疾病数十年。2015年，欧洲药品管理局重新评估了该药的临床效益风险比。
有哪些与支气管肺疾病治疗相关的氨溴索新科学数据？
本综述基于2006 - 2015年发表期间在医学期刊数据库中以“氨溴索”为检索词进行的系统文献研究。手动排除不相关的出版物。
氨溴索仍在深入研究中。其作为祛痰剂的传统适应证得到确认。但人们对其各种作用机制以及所研究结构的建模也有了更深入的了解。可以设想新的应用领域，例如在接受手术或重症监护的重症肺病患者中，作为抗感染治疗的辅助药物，尤其是在感染产生物膜病原体的情况下，或在罕见病如溶酶体贮积病中。然而，这些应用领域临床相关性的最终证据仍然缺乏。
